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Abstract
Background: Although the significance of preoperative nutritional status has been investigated, there is no report
regarding the relationship of their postoperative changes on outcomes in patients who underwent radical cystectomy
for bladder cancer. Here, we report the clinical impact of the change, from baseline, in nutritional status and volume of
abdominal skeletal muscle mass and adipose tissue after radical cystetomy.
Methods: A retrospective analysis of 89 patients with bladder cancer, who underwent curative radical cystectomy, was
conducted to assess the time course of change, from baseline, in body composition and nutritional status at 1, 3, 6, 12,
and 24 months, after surgery. Skeletal muscle mass and abdominal adipose tissue mass were quantified by unenhanced
computed tomography images. Two different nutritional indices, the Prognostic Nutritional Index and the Controlling
Nutritional Status score were calculated from laboratory blood tests. We evaluated the prognostic value of the rate of
change in the body composition and nutritional status after radical cystectomy.
Results: The cross-sectional area at the level of the third lumbar vertebra of the psoas major muscle and nutritional
indices showed a transient deterioration at 1 and 3 months after radical cystectomy, with a return to baseline values
from 6 to 24 months. A ≤ −10% loss in the area of the psoas muscle was associated with a shorter overall survival,
compared to those with a > −10 change [hazard ratio (HR) 2.2, P = 0.02]. Multivariate analyzes identified sarcopenia
status at baseline (HR 2.2, P = 0.03) and a ≤ −10% loss in the psoas muscle (HR 2.4, P = 0.02) were identified as
independent prognostic factors for overall survival. A subanalysis of patients without sarcopenia identified a worse
survival outcome for patients with a ≤ −10% loss in the psoas muscle (HR 2.6, P = 0.03) and ≤ − 5 change in the
Prognostic Nutritional Index (HR 3.6, P = 0.01).
Conclusion: Further research is required to establish appropriate rehabilitation protocols and nutritional interventions
after radical cystectomy for maintaining skeletal muscle mass and nutrition status which could counteract physical
deterioration and improve outcomes.
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Background
Urothelial carcinoma of the bladder (UCB) is the sixth
most frequent neoplasm in men [1]. Radical cystectomy
(RC), with or without perioperative systemic chemother-
apy, is the standard treatment for selected T1 high-grade
and muscle invasive bladder cancer (≥T2; MIBC) [2, 3].
Both postoperative complication and mortality are signifi-
cant concerns in these patients. Simple and specific factors
predictive of postoperative complications and mortality
are required to improve clinical outcomes after RC.
Over the past decade, studies have evaluated the rela-
tionship between postoperative complication and/or mor-
tality and several preoperative factors, including body
mass index (BMI), nutritional status, inflammation, host
immunity, skeletal muscle mass (i.e., sarcopenia) and
abdominal adipose tissue, in various malignant diseases,
including bladder, upper urinary tract, kidney, prostate,
colorectal, and hepatocellular carcinoma [4–14]. Specific-
ally with regards to the effects of sarcopenia on postopera-
tive outcomes, the clinical definition of age-related
sarcopenia developed by The European Working Group
on Sarcopenia in Older People (EWGSOP) in 2010 has
been used, which bases the diagnosis of sarcopenia on
documentation of low muscle mass, low muscle strength
and low physical performance [15].
Loss of muscle mass can easily be evaluated using ab-
dominal computed tomography (CT), which is routinely
performed as part of an oncological evaluation. There-
fore, majority of studies have evaluated the impact of
baseline measures in skeletal muscle mass and physical
function, that were obtained before surgery and/or onco-
logical treatment, on postoperative complications, prog-
nosis and treatment outcomes in patients after systemic
chemotherapy or radical surgery [7, 8, 12, 16–19]. To
date, however, the associations of change, from baseline,
in skeletal mass and adipose tissue on prognosis and
treatment outcomes have not been evaluated in patients
with UBC undergoing RC.
As concurrent urinary diversion requiring intestinal
anastomosis, such as ileal conduit and orthotopic neoblad-
der, is performed as part of an RC, an accurate evaluation
of preoperative nutritional status is an essential compo-
nent of the preoperative evaluation. The preoperative
immune-nutritional status, including the prognostic nutri-
tional index (PNI) [20] and the Controlling Nutritional
Status (CONUT) score [13], has been reported to correl-
ate with survival and postoperative complications in pa-
tients with colorectal cancer. These scores are calculated
from the serum albumin, the peripheral lymphocyte count
and total cholesterol (T-chol). Although the clinical
relevance of the PNI and CONUT has previously been in-
vestigated in other malignancies [13, 20], there is no re-
port regarding the relationship of these preoperative and
postoperative nutritional scores on outcomes after RC.
Therefore, the aim of our study was to perform a compre-
hensive analysis of the change, from baseline, nutritional
status, volume of abdominal skeletal muscle mass/adipose
tissue and its effect on the postoperative prognosis of pa-
tients who underwent RC for UCB.
Methods
Patient selection and data collection
Between January 2006 and October 2014, 105 UCB cases,
without evidence of distant metastases, underwent cura-
tive RC. Sixteen cases were excluded because of insuffi-
cient radiographic and laboratory examination, leaving the
data from 89 cases to be included in our retrospective
analysis. The histopathological review was conducted by
an experienced uropathologist (KS) to determine the T
category (2010 AJCC TNM Staging system), tumor grade
(2004 WHO classification) and presence of variant hist-
ology. Clinicopathological variables and laboratory data
obtained at baseline and at all time points of measurement
postoperatively were extracted from medical records for
analysis of the time-course of change after surgery.
Among the 89 cases, 37 (42%) and 14 (16%) received 2 or
3 cycles of platinum-based neoadjuvant chemotherapy
and adjuvant chemotherapy, respectively.
Body composition index by CT scan
Unenhanced CT images, performed for diagnostic or
follow-up purposes, were used as inputs into the Volume
Analyzer SYNAPSE VINCENT image analysis system
(Fujifilm Medical, Tokyo, Japan) to quantify the body
composition index. Measured variables were normalized
to height (m2) and were expressed in cm3/m2 or cm2/m2
for between-subject comparisons. The following mea-
sures were obtained for analysis: total psoas major muscle
volume (cm3/m2); partial volume of the psoas major
muscle at the level of the third and fourth lumbar vertebra
(L3-L4; cm3/m2); area of the psoas major muscle at L3
(cm2/m2); total area of the abdominal skeletal muscle
(cm2/m2); and the volume of abdominal adipose tissue,
commonly referred to as the volume of subcutaneous and
visceral fat (cm3/m2). The visceral-to-subcutaneous adi-
pose tissue volume ratio (VSR) was calculated to deter-
mine the distribution of abdominal adipose tissue.
Representative images used for analyses of abdominal
muscle and fat are shown in Fig. 1a-c.
Skeletal muscle index and definition of sarcopenia
Abdominal skeletal muscles include the psoas major,
paraspinals (erector spinae and quadratus lumborum),
and muscles of the abdominal wall (transversus abdomi-
nus, external and internal obliques, and rectus abdomi-
nus). The cross-sectional area of skeletal muscle at the
level of L3 (cm2), which was identified using Hounsfield
unit thresholds of −30 to +150, was normalized to height
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(m2) to yield the skeletal muscle index (SMI), expressed
in cm2/m2 (Fig. 1d) [16]. Image analysis was performed
by two independent investigators (MM and YM) who
were blinded to other parameters and outcomes at the
time of measurement. Martin’s definition of the SMI
[21] was adopted in our analysis as it is based on a large
cohort and, therefore, would be applicable to various
cancer patients with different BMI profiles, as follows:
SMIs of <43 cm2/m2 for males with a BMI <25 kg/m2;
<53 cm2/m2 for males with a BMI ≥25 kg/m2; and
<41 cm2/m2 for females.
Nutrition index
The baseline blood data were obtained the day before
RC. The PNI was calculated using the following formula:
10 × serum albumin (g/dl) + 0.005 × total lymphocyte
count (per mm3) [18]. The CONUT score was deter-
mined on the basis of the serum albumin, peripheral
lymphocyte count and the T-cholesterol, as previously
described (Table 1) [22]. Both indices were reported as
continuous variable for analysis. Cutoffs for the PNI and
CONUT scores were set to the lower quartile and higher
quartile values among the study group, respectively,
based on the interquartile range (IQR).
Follow-up and time-course of change in variables after RC
Postoperative follow-up was performed at the following
time points, according to our institutional protocol:
1 month, every 3 months for the first 2 years, every
6 months for the following 3 years, and annually there-
after for patients without evidence of recurrent disease
[23]. Oncological evaluation included physical examin-
ation, routine blood tests, urine cytology, and CT scan of
the chest, abdomen and pelvis. Body composition vari-
ables and nutritional index were retrospectively deter-
mined and their postoperative time-course change, from
baseline, was calculated by absolute value and relative
value analysis, with baseline data set to 100%.
Fig. 1 Representative images for the body composition indexVolume Analyzer SYNAPSE VINCENT image analysis system was used to reconstruct
three-dimensional (3-D) images as follow: a, red area indicates abdominal adipose tissue (visceral fat and subcutaneous fat), with the green area
indicating the total volume of the psoas major muscle; b, quantification of the partial volume of the psoas major muscle at the level of L3-L4; c,
cross-sectional area of the psoas major muscle at the level of L3 (green ovals indicated by yellow arrows); and d, cross-sectional 2-D images at
the level of L3 were used to quantify the skeletal muscle index (SMI). The green shadows indicate the abdominal skeletal muscle areas
Table 1 Scoring table for the CONUT score
Variables Malnutrition degree
None Mild Moderate Severe
Serum albumin (g/dL) ≥ 3.5 3.00–3.49 2.50–2.99 < 2.5
Score 0 2 4 6
Total lymphocyte count (/mm3) ≥ 1600 1200–1599 800–1199 < 800
Score 0 1 2 3
Total cholesterol (mg/dL) ≥ 180 140–179 100–139 < 100
Score 0 1 2 3
CONUT = controlling nutritional status; cited from de Ulibarri Perez JI, et al. Nutr Hosp [22]
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Statistical analysis
Data were expressed by bar charts or box plots, and
evaluated using Student’s t-test or the Mann–Whitney
U-test as appropriate for the dataset. Disease-specific
survival (DSS) and overall survival (OS) were estimated
using the Kaplan–Meier method and compared using
the log-rank test or log-rank test for trend analysis.
Multivariate analysis was used to identify independent
prognostic variables using a stepwise Cox proportional
hazards regression model. Variables significantly affect-
ing mortality (P < 0.05) in univariate analysis were in-
cluded in the multivariate analysis. IBM SPSS Version
21 (SPSS Inc., Chicago, IL, USA) and PRISM software
version 5.00 (San Diego, CA, USA) were used for statis-
tical analyzes and plotting the data, respectively. A P
value <0.05 was considered statistically significant.
Results
Patient characteristics and the relationship with
sarcopenia
The baseline clinicopathological variables, nutritional
index, blood test results, and the administration of neoaju-
vant/adjuvant chemotherapy for the 89 cases included in
our analysis are summarized in Table 2. The median
follow-up period after RC for the survival analysis was
29 months (IQR, 10–60). Over the follow-up period, 35
patients (39%) died, 25 (28%) of UCB. The mean ± SD
(cm2/m2) SMI before RC in men and women, respectively,
was 52.1 ± 11.1 and 46.9 ± 7.6. Twenty two patients (25%)
were diagnosed with sarcopenia in our study cohort. Base-
line variables were compared between patients with and
without sarcopenia (Table 2). Sarcopenia status was asso-
ciated to a lower BMI and clinical T4 category, while there
was a marginal association of sarcopenia status with a
lower PNI, a lower hemoglobin, and a lower sodium.
The baseline body composition and nutritional indices
The median (IQR) and mean ± SD of the abdominal
muscle index, the abdominal adipose tissue index,
and the nutritional indices at baseline are listed in
Additional file 1: Table S1. Although there was no
sex-specific difference in BMI, the visceral fat index,
PNI and CONUT score, significant sex-specific dif-
ferences were identified for all abdominal muscle
indices with higher abdominal muscle indices in
males, with the subcutaneous fat index and VSR be-
ing higher in females. Based on this result, relative
values (expressed as a percentage of the baseline,
which was set at 100%) were more appropriate to plot
the data of male and female patients all together in
the analysis of the postoperative change, from base-
line, in body composition index than absolute values.
Postoperative time course of change in body composition
and nutritional indices
The change from baseline to 24 months after RC was
plotted on line graphs (Fig. 2a-h), with absolute values
shown in Additional file 2: Figure S1. A transient deteri-
oration was identified for most variables at 1 and 3 months
after RC, with the majority of scores recovering to baseline
values over time. Although the SMI (all abdominal
skeletal muscle volume at L3) exhibited little deterioration
(Fig. 2d), the decrease in the psoas major muscle area at
L3 remained significant at 3 months (Fig. 2c). A similar
trend was seen in changes of two abdominal fat index and
VSR (Fig. 2e-g).
Of 89 patients, 71 (80%) underwent ileal conduit, 1
(1%) underwent orthotopic ileal neobladder, and 17
(19%) underwent uretero-cutaneostomy. The former two
requires intestinal anastomosis, while the latter does not.
To test whether urinary diversion method affects time-
course changes in skeletal muscle volume and nutrition
status, we compared their changes between ileal con-
duit/neobladder and cutaneostomy (Fig. 3). Similar ana-
lyses were performed for the administration of adjuvant
and neoadjuvant chemotherapy (Additional file 3: Figure
S2 and Additional file 4: S3). However, none of urinary
diversion method, adjuvant chemotherapy, and neoadju-
vant chemotherapy affected significantly the changes in
skeletal muscle volume and nutrition status.
Both nutritional indices showed a significant transient
deterioration at 1 and 3 months after RC (Fig. 2h and i).
We hypothesized that the extent of the partial volume
loss of the psoas major muscle at L3 and the deterior-
ation in nutritional indices after RC would be associated
with a worse prognosis, as previously reported in a co-
hort of patients with colorectal cancer and lung cancer
treated with chemotherapy [16, 19]. The postoperative
time course of change in the area of the psoas major
muscle area at L3 is shown in Fig. 4a for two representa-
tive patients. Median (IQR) points of maximal change
during 1–3 months from baseline for the partial volume
of psoas major muscle at L3 and for the PNI and
CONUT score were −10.0% (−44.6 to −0.1), −5.0 (−20.3
to −0.3) and +2 (−3 to +4), respectively. The cutoff
values for change after RC were determined based on
median values as follows: −10% (partial psoas volume),
−5 points (PNI) and 2 points (CONUT score). Patients
experiencing a ≤ −10% loss in the volume of the psoas
muscle after RC had a significantly shorter OS, whereas a
change of ≤ − 5 on the PNI and ≥2 on the CONUT score
was not associated with a worse survival outcome (Fig. 4b).
In a subanalysis of patients without sarcopenia (n = 67),
DSS and OS were significantly worse in patients experien-
cing a ≤ −5 change in the PNI, compared to those with
> − 5 change in PNI (Fig. 4b). A ≤ −10% loss in the volume
of the psoas muscle was associated with a shorter OS in all
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analyzes, including the entire cohort and subanalyzes
for patients with and without sarcopenia (Fig. 4B). No
prognostic effect of the CONUT score was identified.
The Kaplan–Meier curves for DSS and OS are shown
in Additional file 5: Figure S4.
We also evaluated the correlation between the num-
ber of days of hospitalization after RC and postopera-
tive loss in psoas major muscle volume, decrease in
the PNI and increase in the CONUT score (Fig. 4c-e).
Both postoperative muscle loss and deterioration in
Table 2 Characteristics and correlation with sarcopenia in 89 patients undergoing radical cystectomy
Variables Total cases, n (%) Non-sarcopenia, n (%)† Sarcopenia, n (%) † P value ¶
Total cases 89 (100%) 67 (75%) 22 (25%) -
Age at RC (year-old), median (IQR) 71 (48–83) 72 (66–75) 71 (62–76) 0.22
BMI (Kg/m2), median (IQR) 22.7 (20.9–24.7) 23.3 (21.6–24.75) 21.8 (19.3–23.0) 0.013
Sex 0.16
Male 70 (79%) 55 (82%) 15 (68%)
Female 19 (21%) 12 (18%) 7 (32%)
ECOG-PS 1.0
0 82 (92%) 62 (93%) 20 (91%)
≥ 1 7 (8%) 5 (7%) 2 (9%)
Clinical T category 0.007
NMIBC 6 (7%) 2 (3%) 4 (18%)
T2 42 (47%) 36 (54%) 6 (27%)
T3 19 (21%) 16 (24%) 3 (14%)
T4 22 (25%) 13 (19%) 9 (41%)
Clinical N category 0.83
0 78 (88%) 59 (88%) 19 (86%)
≥ 1 11 (12%) 8 (12%) 3 (14%)
Variant histology 0.21
No 68 (76%) 49 (73%) 19 (86%)
Yes 21 (24%) 18 (27%) 3 (14%)
Preoeprative nutrition index,
median (IQR)
PNI 47.0 (43.5–50.2) 47.5 (44.0–51.0) 45.2 (38.8–48.6) 0.08
CONUT score 2 (1–3) 2 (1–3) 2 (1–3) 0.30
Preoeprative blood level,
median (IQR)
Hb (g/dL) 11.2 (10.2–12.7) 11.6 (10.4–12.7) 10.8 (9.8–12.1) 0.07
CRP (mg/dL) 0.2 (0.1–0.7) 0.2 (0.1–0.6) 0.4 (0.1–1.7) 0.20
Albumin (g/dL) 4.0 (3.7–4.2) 4.0 (3.8–4.2) 3.9 (3.6–4.2) 0.47
Sodium (mEq/L) 141 (139–143) 141 (139–143) 140 (138–143) 0.09
LDH (U/L) 180 (159–201) 180 (159–201) 181 (139–205) 0.54
Neoadjuvant chemotherapy 0.23
No 52 (58%) 38 (57%) 14 (64%)
Yes 37 (42%) 29 (43%) 8 (36%)
Adjuvant chemotherapy 0.42
No 75 (84%) 56 (84%) 19 (86%)
Yes 14 (16%) 11 (16%) 3 (14%)
RC radical cystectomy; IQR interquartile range; ECOG-PS Eastern Cooperative Oncology Group-Performance Status, NMIBC non-muscle invasive bladder cancer
(T1/isolated Tis), BMI body mass index, PNI prognostic nutritional index, CONUT controlling nutritional status, Hb hemoglobin, CRP C-reactive protein LDH
lactate dehydrogenase
† According to the definition for the Martin's definition [21]
¶ Comparison between non-sarcopenia cases and sarcopenia cases female with Mann-Whitney U test or chi-squared test
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Fig. 2 Time course of change in the body composition and nutrition indices after radical cystectomy. a, total volume of the psoas major muscle; b,
partial volume of the psoas major muscle at the level of L3-L4; c, cross-section area of the psoas major muscle at the level of L3; d, abdominal skeletal
muscle area at the level of L3, referred as skeletal mass index (SMI); e, volume of abdominal visceral fat; f, volume of abdominal subcutaneous fat; g,
visceral-to-subcutaneous ratio (fat distribution); h, the PNI; and i, the CONUT score. Relative values are used for the body composition indices (a-g), and
raw values for nutrition indices (h and i). For the body composition indices, the time course of change in absolute values is shown in Fig. S1. Data are
expressed as means and standard deviations. Scores at each time point (1, 3, 6, 12, and 24 months after radical cystectomy) were compared to baseline
(BL) scores using the Wilcoxon signed-rank test: *, P < 0.05; **, P < 0.01; and ***, P < 0.001
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nutritional indices were significantly related to a lon-
ger duration of hospitalization after RC.
Multivariate analysis for prognostic impact of psoas
muscle loss
To explore the prognostic impact of preoperative sa-
rcopenia status, as well as of the postoperative volume
loss of psoas muscle, we performed univariate analyzes
followed by multivariate analysis (Table 3). Univariate
analysis identified T4 category, N positive and sarcope-
nia as prognostic variables for DSS, with T4 category, N
positive, sarcopenia, and postoperative volume loss of
the psoas muscle identified as prognostic factors of OS.
Multivariate analysis, controlling for possible confound-
ing factors, identified positive N [hazard ratio (HR) 3.1,
P = 0.02] as an independent prognostic factor of DSS,
and sarcopenia status at baseline (HR 2.2, P = 0.03) and
a 10% loss in the volume of the psoas muscle (HR 2.4,
P = 0.02) as an independent prognostic factor of OS.
Neither sarcopenia status at baseline nor a 10% loss in
the volume of the psoas muscle were identified as inde-
pendent prognostic factors for DSS in this study
(P = 0.14 and 0.11, respectively).
Discussion
There is accumulating evidence supporting the relevance
of host immunity, response and inflammation to tumor
progression and disease prognosis [24]. Sarcopenia is a
multifactorial syndrome that is defined as a loss of skeletal
muscle mass and low physical performance [15]. Skeletal
muscle loss is a critical physiological change underlying
wasting and frailty, resulting in poor clinical outcomes for
acute illness and malignant diseases [8, 9, 24]. In addition
to wasting of skeletal muscle mass, nutritional status and
body composition, including the volume of adipose tissue,
have been related with worse clinical and disease prognosis
[11, 13, 14, 20, 21]. In our study, we investigated the clinical
relevance of baseline and postoperative time course of
change in body composition and nutritional indices as
prognostic biomarkers to predict DSS and OS in patients
with UCB undergoing RC.
Baseline sarcopenia, defined by a low SMI, was associ-
ated with poor DSS and OS after RC in univariate analyses
(Table 3). There was a significant association between sar-
copenia status and T4 stage tumor (Table 2). Similar find-
ings have previously been reported in patients with gastric
cancer [13], with a higher rate of T3 and T4 among pa-
tients with a positive sarcopenia status at baseline. Body
weight loss, a poor nutritional status and decreased Hb
are known to be markers of cancer cachexia [25]. Eleva-
tion of inflammatory proteins, such as interleukin (IL)-6
and tumor necrosis factor alpha (TNF-α), may lead to
various physical changes, including a decrease in muscle
mass and adipose tissue in patients with sarcopenia.
Fig. 3 Comparison of changes after radical cystectomy between ileal conduit/neobladder group and uretero-cutaneostomy group.Time-course
changes in cross-section area of the psoas major muscle at the level of L3 (a), abdominal skeletal muscle area at the level of L3 (b), the PNI (c)
and, the CONUT score (d). Data of ileal conduit/neobladder group (red) and cutaneostomy group (blue) conduit are plotted by means ± SD.
Scores of two groups compared in each time point by the Mann-Whitney U-test. ns, not significant
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Only a few reports have evaluated the clinical impact
of a change in nutritional status and body composition
after surgery and during oncological treatment. Previous
studies have reported on changes in skeletal muscle
mass during chemotherapy in patients with unresectable
colorectal cancer [16] and advanced lung cancer [19],
changes in skeletal muscle and adipose tissue in gastric
cancer patients undergoing total gastrectomy [18] and
changes in muscle, fat and bone mass during androgen
blockade in prostate cancer patients [17, 26].
Notably, Hanson et al. provided evidence of the effect-
iveness of strength training in contributing to gains in
muscle mass and strength, with these gains being associ-
ated with improved quality of life in patients with pros-
tate cancer treated by androgen blockade [17]. Here, we
hypothesized that decreases in the volume of the psoas
major muscle and abdominal fat tissue, as well as nutri-
tional status was associated with poor clinical outcomes,
which could be improved with appropriate interventions.
We identified a transient decrease in the volume of the
psoas major muscle and abdominal fat tissue, as well as
deterioration in the two nutritional indices, at 1 and
3 months after RC (Fig. 2). Interestingly, no postopera-
tive decrease in the total area of abdominal skeletal
muscles (sum of areas for the psoas major, paraspinal
and abdominal wall muscles) was identified after RC
(Fig. 2d). Therefore, targeted assessment of the psoas major
muscle, postoperatively, could provide a proxy measure of
physical deterioration after RC. Moreover, a postoperative
loss in the volume of the psoas major muscle was identified
as a strong prognostic factor of OS in our subanalysis
among patients with and without sarcopenia (Fig. 3 and
Figure S2). Our result was almost consistent with previous
studies demonstrating the role of psoas muscle mass as a
prognostic factor after RC [6, 7, 27].
Although a postoperative decrease in the PNI did not
have prognostic value in the whole cohort, a decrease in
PNI was identified as prognostic factor among patient
Fig. 4 Prognostic impacts of postoperative psoas muscle loss and nutritional deterioration. a. Time course of change (from baseline to 3 and 6 months) in
the area of the psoas major muscle at the level of L3, on CT images, is shown for two representative patients. Case 1 (60 year-old man diagnosed with
pT2a high-grade UC with nested variant) showed a 4% loss in muscle volume. There was no evidence of recurrence of metastases at 80 months after
radical cystectomy. Case 2 (72 year-old man with pT3a high-grade pure UC) showed a 25% loss in muscle volume. A metastatic lesion was detected in the
ileum at 31 months after cystectomy, and the patient died of bladder cancer at 54 months after radical cystectomyb. Impact of postoperative nutritional
deterioration and psoas major muscle loss evaluated across all patients. A subanalysis according to sarcopenia status at baseline was performed. Hazard
ratio and 95% confidence interval are plotted in the Table. P values are based on the comparison using the log-rank test. PNI, prognostic nutrition index;
CONUT, Controlling Nutritional Status; DSS, disease-specific survival; OS, overall survival.c-e. The correlation between days of hospitalization
after RC postoperative loss in volume of the psoas major muscle (c), decrease in PNI (d), and increase in CONUT score (e). The correlation was
examined using Spearman’s correlation; Spearman ρ values and the 95% confidence intervals are shown in the Figures.
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without sarcopenia (Fig. 3b). The low baseline PNI
among patients with sarcopenia could limit the postop-
erative change in reaching significant, providing a likely
explanation for between-group differences with regards
to the prognostic value of PNI. Moreover, there was a
significant association of postoperative muscle loss and
deterioration in nutrition status with a longer duration
of hospitalization after RC (Fig. 3c-e). Therefore, efforts
to prevent complications and shorten hospitalization
period, as possible, are required to improve clinical out-
comes after RC.
The limitations of our study need to be acknowledged
in the interpretation of our results. These include data
from a single-institution, the retrospective nature of the
study, including the potential selection bias, and analysis
with relatively small sample size and short follow-up
Table 3 Univariate and multivariate analysis of prognostic variables in 89 cases undergoing radical cystectomy
Variables Disease-specific survival Overall survival
Univariate Multivariate Univariate Multivariate
HR 95% CI P value HR 95% CI P value HR 95% CI P value HR 95% CI P value
Age at RC
≤ 70 1 1
> 70 1.9 0.8–4.2 0.12 1.7 0.8–3.3 0.15
Sex
Male 1 1
Female 1.4 0.5–3.8 0.52 1.3 0.5–3.0 0.57
Clinical T
NMIBC 1 1 1 1
T2 3.1 0.2–39.7 0.38 0.8 0.09–7.0 0.84 1.3 0.2–8.2 0.8 1.3 0.2–11.5 0.78
T3 3.5 0.2–54.0 0.36 0.7 0.08–6.7 0.72 1.1 0.2–9.2 0.9 0.97 0.2–4.9 0.98
T4 4.0 1.2–13.7 0.03 4.1 0.5–35.4 0.20 3.1 1.1–8.8 0.04 6.7 0.8–56.9 0.08
Clinical N
N0 1 1 1 1
N+ 11.3 2.8–45.7 0.0006 3.1 1.2–7.8 0.02 3.9 1.2–12.5 0.02 1.9 0.8–4.5 0.15
Variant histology
Negative 1 1
Positive 0.9 0.3–2.2 0.76 0.9 0.4–1.9 0.73
Neoadjuvant chemotherapy
No 1 1
Yes 0.7 0.3–1.5 0.35 0.7 0.3–1.5 0.35
Adjuvant chemotherapy
No 1 1
Yes 1.8 0.6–5.3 0.28 0.7 0.4–1.4 0.72
Sarcopenia status †
No 1 1 1 1
Yes 2.7 1.1–7.2 0.048 1.9 0.8–4.5 0.14 2.3 1.1–5.3 0.046 2.2 1.1–4.6 0.03
Psoas major muscle loss
> −10% 1 1 1 1
≤ −10% 2.2 0.99–4.8 0.052 2.0 0.9–4.7 0.11 2.2 1.2–4.4 0.02 2.4 1.2–4.9 0.02
HR hazard ratio, CI confidence interval, RC radical cystectomy, NMIBC non-muscle invasive bladder cancer (T1/isolated Tis)
† According to the definition for the Martin's definition [21]
Miyake et al. BMC Cancer  (2017) 17:237 Page 9 of 11
duration. As well, definitions of muscle loss and deteri-
oration in nutritional status, although used in previous
studies, remain controversial. Optimal cutoffs need to be
validated in an independent multi-institutional sample
to establish a novel risk assessment tool specific to RC.
Conclusions
To our knowledge this is the first study to have evalu-
ated the clinical relevance of postoperative change in
body composition, including skeletal muscle mass and
nutritional status, as a predictor of clinical outcomes
and survival after RC. Further research should identify
appropriate rehabilitation protocols and nutritional in-
terventions to maintain skeletal muscle mass and nutri-
tional status, which could counteract deterioration in
physical status and improve outcomes after RC.
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Additional file 2: Figure S1. Time course of change in the body
composition and nutritional indices after radical cystectomy. For the
body composition indices, the time course of change in absolute values
is plotted. Data are expressed as means and standard deviations. Scores
at each time point (1, 3, 6, 12, and 24 months after radical cystectomy)
were compared to baseline (BL) scores using the Wilcoxon signed-rank
test: *, P < 0.05; **, P < 0.01; and ***, P < 0.001. (TIFF 4267 kb)
Additional file 3: Figure S2. Comparison of changes after radical
cystectomy between adjuvant chemotherapy-treated group and non-
treated group.Time-course changes in cross-section area of the psoas
major muscle at the level of L3 (a), abdominal skeletal muscle area at the
level of L3 (b), the PNI (c) and, the CONUT score (d). Data of adjuvant
chemotherapy-treated group (red) and non-treated group (blue) are plot-
ted by means ± SD. Scores of two groups compared in each time point
by the Mann-Whitney U-test. ns, not significant. (TIFF 7216 kb)
Additional file 4: Figure S3. Comparison of changes after radical
cystectomy between neoadjuvant chemotherapy-treated group and non-
treated group. Time-course changes in cross-section area of the psoas
major muscle at the level of L3 (a), abdominal skeletal muscle area at the
level of L3 (b), the PNI (c) and, the CONUT score (d). Data of neoadjuvant
chemotherapy-treated group (red) and non-treated group (blue) are plot-
ted by means ± SD. Scores of two groups compared in each time point
by the Mann-Whitney U-test. ns, not significant. (TIFF 7424 kb)
Additional file 5: Figure S4. Kaplan-Meier curves for disease-specific
survival and overall survival. Kaplan-Meier curves for disease-specific sur-
vival (DSS) and overall survival (OS) were compared for the postoperative
change in the PNI (a), CONUT score (b), and psoas muscle mass (c). The
cutoff values for postoperative change after RC was set based on me-
dian values as follows: −10%, −5 points and 2 points, respectively. The
following separate analyzes were performed: all patients (left panels),
patients without sarcopenia (middle panels), and patients with sarcopenia
(right panels). Survival curves are compared using the log rank test.
(TIFF 13821 kb)
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